Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4222018 | 0.92 | L3MBTL1 (0.42) | BRD4SYKL3MBTL1PKMPLA2G2A | |
| SCHEMBL4220227 | 0.88 | BRD4 (0.44) | BRD4SYKL3MBTL1NPSR1PLA2G2A | |
| SCHEMBL4220932 | 0.87 | HTT (0.46) | BRD4L3MBTL1NPSR1WDR5HTT | |
| SCHEMBL5044656 | 0.84 | BRD4 (0.36) | BRD4L3MBTL1NPSR1PKMPLA2G2A | |
| SCHEMBL5044658 | 0.84 | BRD4 (0.36) | BRD4L3MBTL1NPSR1PKMPLA2G2A | |
| SCHEMBL4213424 | 0.84 | L3MBTL1 (0.42) | BRD4L3MBTL1PKMPLA2G2AHTT | |
| SCHEMBL5048604 | 0.84 | HTT (0.45) | BRD4L3MBTL1NPSR1WDR5HTT | |
| SCHEMBL4210774 | 0.83 | MAOB (0.47) | BRD4NPSR1HTT | |
| SCHEMBL14011412 | 0.83 | BRD4 (0.35) | BRD4L3MBTL1NPSR1PKMPLA2G2A | |
| SCHEMBL4208245 | 0.82 | BRD4 (0.42) | BRD4NPSR1PKMATMWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456288-B2 | Heterocyclic compounds and methods of making and using thereof | REDDY US THERAPEUTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040163-A1 | HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE) | DR. REDDY'S LABORATORIES LTD (IN) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | PYGM, MYLK, HMOX1 | BRD4 784/4885SYK 1773/4885L3MBTL1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.